Milestone Pharmaceuticals is trading 5.06% down now at $0.82 amid broader risk-off pressure driven by elevated Treasury yields and renewed interest-rate concerns.
- No clear negative company-specific catalyst was identified.
- On September 24, 2026, the company announced the first Canadian participant enrolled in its ReVeRA-301 Phase 3 trial; the constructive update does not explain the decline.
- Growth-oriented assets are under pressure, while healthcare is outperforming, suggesting macro sentiment rather than sector weakness is the likeliest driver.